PDF(Pubmed)
Abstract：
On 5 June this year the first field trial of a CRISPR-Cas-9 gene-edited crop began at Rothamsted Research in the UK, having been approved by the UK Department for Environment, Food & Rural Affairs. However, in late July 2018, after the trial had started, the European Court of Justice ruled that techniques such as gene editing fall within the European Union\'s 2001 GMO directive, meaning that our gene-edited Camelina plants should be considered as genetically modified (GM). Here we describe our experience of running this trial and the legal transformation of our plants. We also consider the future of European plant research using gene-editing techniques, which now fall under the burden of GM regulation, and how this will likely impede translation of publicly funded basic research.
摘要：
今年6月5日，英国RothamstedResearch开始了CRISPR-Cas-9基因编辑作物的首次田间试验，已获得英国环境部的批准，食品和农村事务。然而,2018年7月下旬，审判开始后，欧洲法院裁定，基因编辑等技术属于欧盟2001年转基因指令，这意味着我们的基因编辑的Camelina植物应被视为转基因（GM）。在这里，我们描述了我们进行此试验的经验以及工厂的法律转型。我们还考虑了使用基因编辑技术进行欧洲植物研究的未来，现在属于转基因监管的负担，以及这将如何阻碍公共资助的基础研究的翻译。
